The US Food and Drug Administration (FDA) has granted accelerated approval to Pfizer’s Elrexfio (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). The drug is approved in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory… Read More
Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. Sosei Group and Cancer Research UK announced that the first patient has been dosed in a Phase I/IIa clinical trial evaluating… Read More
Listen to this article on the DDW Podcast: Genoscience Pharma’s Philippe Halfon and Eric Raymond share their expertise on targeting the recycling of unsustainable production of palmitoylated cancer-associated proteins. Cancer relies on palmitoylation for progression Palmitoylation is a global post-translational lipid modification, that controls the localisation, stability, and function of several proteins. Read More
Scientists have unveiled the first and largest encyclopaedia of protein alterations in soft tissue sarcomas – opening the door to a new era of understanding and treatment for this group of rare cancers. The pioneering encyclopaedia, or ‘Rosetta Stone’, of sarcoma biology compiles a wealth of… Read More
Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. The findings, which suggest that the approach has the potential to be effective against tumours… Read More
This World Lung Cancer Day, DDW’s Diana Spencer takes a look at five 2023 discoveries that could transform the treatment of lung cancer in the near future. Allogeneic cell vaccines In July 2023, Lineage Cell Therapeutics and Cancer Research UK announced encouraging primary and secondary endpoint… Read More
A potent anti-cancer therapy has been created using Nobel prize-winning “click chemistry”, in a new study by University College London (UCL) and Stanford University researchers. The study, published in Nature Chemistry, opens up new possibilities for how cancer immunotherapies might be built in… Read More
Listen to this article on the DDW Podcast: DDW’s Megan Thomas spoke with Frédéric Triebel, the French immunologist/oncologist who is best known for his 1990 discovery of the LAG-3 immune control mechanism. Triebel shares insights from his career, expands on his experience with the company he founded, Immutep, and comments on the… Read More
A global study, led by University College London (UCL) and University College London Hospitals (UCLH) and sponsored by Roche, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer (NSCLC) patients, when compared to single-agent chemotherapy. For… Read More
This is the latest episode of the free DDW narrated podcast, “Immunotherapy, avelumab and protecting the immunocompromised”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Mice with humanised immune systems advance cell-based immunotherapy”, “… Read More
AC Immune has received Fast Track designation from the US Food and Drug Administration (FDA) for its anti-amyloid beta (Abeta) active immunotherapy (vaccine)-candidate, ACI-24.060, for treatment of Alzheimer’s disease (AD). This follows FDA clearance of the Investigational New Drug (IND) application enabling expansion to the USA of the ongoing Phase… Read More
This article is sponsored by Charles River. Research tools, safety testing and regenerative medicines – these endless stem cell applications are powering precision, speed, and new modalities in drug development. Stem cells for use in drug discovery Stem cells are fast becoming an invaluable tool in the drug… Read More
Scientists from Japan have identified regulator CD69, which controls the differentiation of CD8+ T cells within tumour-draining lymph nodes, thereby regulating anti-tumour immunity. Future cancer treatment based on antibodies against CD69 could enhance anti-tumour immune responses of CD8+ T cells and lead to more efficient cancer… Read More
IOME Bio, a seed stage biotechnology company focused on overcoming tumour resistance to immune checkpoint inhibition, has published its foundational research by founders Dr Arlene Sharpe and Dr Dennis Kasper in Nature. By providing evidence of its therapeutic relevance, it reveals insights into the importance… Read More
The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Exact Sciences, Guardant Health, Illumina, MSD and Novartis have come together to launch the European Coalition for Access to Comprehensive Genomic Profiling (ECGP). It is hoped that the Coalition will improve cancer care through increased routine clinical access and… Read More
Janssen has presented new data from across its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Talquetamab Talquetamab is an investigational GPRC5D-directed bispecific antibody currently in clinical development. Updated results from the Phase II MonumenTAL-1 study show that… Read More
